What is Melanotan I approved and used for medically?

Melanotan I, which carries the international nonproprietary name afamelanotide, has exactly one approved medical use: erythropoietic protoporphyria (EPP), a rare inherited photosensitivity disorder. Marketed as Scenesse by Clinuvel Pharmaceuticals, it earned European Medicines Agency authorization in 2014 and United States Food and Drug Administration approval in 2019, in both cases to increase pain-free light exposure in adults with confirmed EPP. Every other use marketed under the Melanotan name is unlicensed and carries no approved indication.

What specific medical condition is the approved form of Melanotan I authorized to treat?

The approved indication names a single disease: erythropoietic protoporphyria, driven most often by a deficiency in the enzyme ferrochelatase. That deficiency lets protoporphyrin IX build up in red blood cells and skin, where visible light triggers a painful phototoxic reaction that can last hours to days, frequently without visible blistering. The label is worded narrowly around this population.

• Underlying defect: Ferrochelatase deficiency allows protoporphyrin IX to accumulate in erythrocytes and skin.
• Trigger: Visible and artificial light absorbed by that compound produces burning, stinging, and swelling.
• Prevalence: EPP is estimated to affect roughly one in tens of thousands of people, usually from early childhood.
• Approved wording: The label targets increased pain-free light exposure in adults, not a cure for the enzyme defect.

Which regulatory agencies have authorized the drug, and in what years?

Two regulators stand behind afamelanotide, and both tied their authorization to the specific EPP indication rather than general availability. The European Medicines Agency cleared it across the European Union in 2014; the United States Food and Drug Administration followed in 2019. The roughly five-year gap is routine for rare-disease products, since each agency reviews its own dossier under its own standard.

What is the biological mechanism that produces its approved therapeutic effect?

The therapeutic effect begins at the melanocortin-1 receptor on pigment-producing melanocytes. Afamelanotide, a structural analog of alpha-melanocyte-stimulating hormone engineered to be more potent and stable than the natural hormone, binds and activates that receptor, shifting melanocytes toward eumelanin, the brown-black pigment that absorbs and scatters light more effectively than lighter pheomelanin. The added eumelanin acts as an optical filter over the protoporphyrin that accumulates in EPP.

1. Receptor binding: Afamelanotide binds and activates MC1R on epidermal melanocytes.
2. Pigment shift: Activation drives production of eumelanin over the lighter pheomelanin.
3. Optical filtering: Higher epidermal eumelanin absorbs and scatters visible light before it reaches accumulated protoporphyrin.
4. Reduced phototoxicity: Less light energy reaching the porphyrin dampens the cascade behind EPP pain and inflammation.

How is the licensed product delivered to patients in clinical practice?

The licensed product is not a self-injected peptide but a controlled-release implant placed by a clinician. Roughly the size of a grain of rice, the rod-shaped biodegradable implant is inserted under the skin above the hip after local anesthetic, using a dedicated applicator. The format suits maintenance therapy, delivering the drug steadily over weeks from a single administration.

• Form: A rod-shaped biodegradable implant about the size of a grain of rice.
• Placement: A trained clinician inserts it subcutaneously above the hip under local anesthetic.
• Dosing interval: One implant is typically repeated about every two months during higher-light seasons.
• Clearance: The implant matrix breaks down and is absorbed, so no removal is required.

What clinical trial evidence supported the regulatory approval decision?

Approval rested on randomized, placebo-controlled trials in adults with EPP that measured tolerance of light, with pain-free time in sunlight as the central outcome tracked through patient diaries. Participants on afamelanotide generally logged more total pain-free time in direct sunlight than those on placebo, with fewer and less severe phototoxic episodes. Reviewers openly flagged the limits of that evidence base.

How does the approved medicine differ from unregulated tanning products sold under a similar name?

The decisive difference is regulatory status: the approved medicine is a licensed pharmaceutical for a diagnosed condition, while products marketed for tanning under the Melanotan name are unlicensed with no authorized medical use. Naming worsens the confusion, since afamelanotide is chemically Melanotan I and is routinely conflated with Melanotan II, a different unapproved peptide sold online. Neither informally sold version carries authorization in any major market.

Beyond its approved indication, what other conditions is the drug being investigated for?

Research on afamelanotide has reached beyond EPP into other conditions where added photoprotection or melanocortin signaling might help, though none has reached approval. The strongest rationale sits with other light-triggered skin disorders, where the same protective eumelanin increase could reduce reactions. All of it remains investigational, confined to preliminary results and off-label or clinical-study settings.

• Other photodermatoses: Polymorphous light eruption and certain porphyria-related photosensitivities, studied on the same eumelanin rationale.
• Vitiligo: Examined, often alongside light therapy, for possible repigmentation, with preliminary results only.
• Non-skin signaling: Exploratory interest in melanocortin pathways in other organ systems, still early and hypothesis-driven.
• Evidence status: None of these has an approved indication; all sit at investigational or off-label level.

What safety monitoring accompanies its medically supervised use?

Supervised use comes with structured monitoring rather than a single prescription. Reported side effects are generally mild, including headache, nausea, fatigue, and implant-site reactions, and clinicians track them across repeat dosing. Because the drug stimulates melanocytes, guidance adds regular skin and mole examinations as standard caution around pigment-acting agents, not evidence of a proven cancer risk.

• Common side effects: Headache, nausea, fatigue, and implant-site reactions, generally mild.
• Skin surveillance: Regular examination of moles and pigmented lesions, given the drug's action on melanocytes.
• Site checks: The implant insertion site is inspected at each visit for healing and local reaction.
• Population-level tracking: The European patient registry pools real-world data to catch uncommon effects a single trial could miss.
• Caution factors: Added caution is documented for patients with a history of skin cancer or significant liver disease.